Format

Send to

Choose Destination
Nat Rev Drug Discov. 2007 Apr;6(4):287-93.

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.

Author information

1
MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307, USA. mtrusheim@cobioconsulting.com

Abstract

The potential to use biomarkers for identifying patients that are more likely to benefit or experience an adverse reaction in response to a given therapy, and thereby better match patients with therapies, is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. In this article, we consider current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers - which we call stratified medicine - and discuss the implications of this approach to future product development strategies and market structures.

PMID:
17380152
DOI:
10.1038/nrd2251
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center